Sosei Heptares
www.sosei.com
Latest From Sosei Heptares
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
Genentech Signs Up Sosei Heptares GPCR Smarts For $1bn+ Deal
The companies have agreed to a multi-year, multi-target research collaboration and license deal to discover and develop medicines that modulate GPCR targets across a range of diseases.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Cancer
- Dermatology
- Gynecological, Urological
- Infectious & Viral Diseases
- Inflammation
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Sosei Group Corp.
- Sosei Co. Ltd.
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Sosei Heptares
- Senior Management
-
Shinichi Tamura, Chmn., Pres. & CEO
Chris Cargill, EVP, CFO
James Taylor, SVP, Bus. Dev.
Malcolm Weir, EVP, Chief R&D Officer
Tim Tasker, MD, EVP, CMO
Barry Kenny, PhD, CBO, Bus. Dev. - Contact Info
-
Sosei Heptares
Phone: (81) 3 5210 3290
PMO Hanzomon 11F
2-1 Kojimachi
Tokyo, 102-0083
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice